Roivant Sciences has launched a new company whose focus is developing potential treatments for serious respiratory diseases. Named Respivant Sciences, it will begin by advancing RVT-1601 as an investigative therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). RVT-1601, formerly known as PA101, is a novel formulation…
News
More than 700 medical experts, pharmaceutical executives, patient advocates, and others are expected to converge on Washington, D.C., next month for the 2018 NORD Rare Diseases & Orphan Products Breakthrough Summit. The Oct. 15-16 event, sponsored by the National Organization for Rare Diseases (NORD), takes place at the…
Long-term treatment with Ofev (nintedanib) can safely slow disease progression in people with idiopathic pulmonary fibrosis (IPF), new four-year data from INPULSIS-ON, an open-label Phase 3 extension trial, show. The findings were reported in “Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from…
Treatment of idiopathic pulmonary fibrosis (IPF) with Esbriet (pirfenidone) leads to stable lung function over two years, according to a real-world study. The data matches previous results from Phase 3 trials. The research, “Functional decline over time in patients with IPF treated with pirfenidone: the…
A comprehensive Swedish study reveals low use and lack of persistence with Esbriet (pirfenidone) treatment among patients with pulmonary fibrosis (PF). Results of this real-world study were presented in a poster titled “Pirfenidone Use in a Swedish Cohort of Patients With Pulmonary Fibrosis” during the…
The National Institutes of Health (NIH) has granted $12 million to researchers at Cedars-Sinai Medical Center to continue studying two lung diseases — idiopathic pulmonary fibrosis and chronic lung allograft dysfunction. Idiopathic pulmonary fibrosis (IPF) is characterized by progressive scarring of lung tissue which leads to difficulty breathing. Chronic lung allograft dysfunction is a complication…
FibroGen’s investigational compound pamrevlumab has received fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF). The agency’s decision follows review of the double-blind PRAISE Phase 2b study (NCT01890265) results, which showed that, over 48 weeks, intravenous…
September is recognized as Pulmonary Fibrosis (PF) Awareness Month, and the Pulmonary Fibrosis Foundation (PFF) is suggesting a host of ways to get involved in increasing awareness for the disease. Last year, PFF’s awareness efforts on social media reached 915,000 people. This year, the organization hopes to increase that…
The American Lung Association is promoting Pulmonary Fibrosis Awareness Month through September with educational videos featuring lung transplant recipient Randy Cooke, who shares his tips and experience in dealing with idiopathic pulmonary fibrosis (IPF), the most common form of the disease. September was originally designated Pulmonary Fibrosis Awareness…
A research team from the University of Arizona (UA) College of Medicine – Tucson was given a $4.4 million grant from the U.S. Department of Defense to study two experimental treatments believed to delay or possibly reverse excessive scar tissue formation in the lungs of patients with…
